Adaptation of the Hypothalamic-Pituitary-Adrenal Axis to Chronic Ethanol StressSpencer R.L. · McEwen B.S.
Department of Neuroendocrinology, Rockefeller University, New York, N.Y., USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
The ability of chronic ethanol stress to alter hypothalamic-pituitary-adrenal (HPA) axis function in a manner similar to that previously reported for other chronic stress treatments was evaluated. Injection of male Sprague-Dawley or Long-Evans rats with ethanol (1–4 g/kg i.p., 20% v/v in saline) resulted in a rapid and large rise in serum corticosterone levels with maximal levels produced by a dose of 2 g/kg ethanol. Higher doses of ethanol did not increase the maximum corticosterone response above those produced by 2 g/kg ethanol but they extended the duration of the peak response. Chronic treatment with ethanol stress (1–3 weeks) produced signs of hyperstimulation of the HPA axis as indicated by adrenal hypertrophy and thymus involution. There was, however, adaptation of the HPA axis to the chronic ethanol treatment. The corticosterone response to ethanol on the last day of treatment was significantly less than on the first day of treatment, even though serum ethanol levels at the time of both measures were equivalent. There also were no signs of impaired negative feedback control of glucocorticoid secretion in the chronic-ethanol-treated rats. They exhibited a normal corticosterone response to 1 h of restraint and a normal shut-off of the stress response. There was also no down-regulation of type I or type II adrenal steroid receptors in the hippocampus of chronic ethanol-stress-treated rats. These studies illustrate the ability of the HPA axis to adapt to chronic stimulation by ethanol stress while maintaining a normal corticosterone stress response and this offers some insight into the degree and duration of glucocorticoid elevation that may be necessary to produce a maladaptation of the HPA axis.
© 1990 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.